Our Science
Predator® Protein Engineering
TRANSFORMING CANCER TREATMENT THROUGH INNOVATION
Our proprietary PREDATOR® protein-engineering technology integrates specialized protein design elements to enhance activity, stability, and tumor
selectivity within a single molecule. Our conditionally-activated cytokines are called INDUKINE™ molecules.
INDUKINE™ molecules are systemically administered in an inactive form and, upon entering the tumor microenvironment, are selectively activated to deliver the full biological potency of cytokines and recruit a powerful anti-tumor immune response. Therefore, INDUKINE™ molecules deliver maximum therapeutic potential while minimizing unwanted off-target effects in non-tumor tissues.
INDUCER Molecules: Next-Generation Conditionally Activated T Cell Engager Design
- Proprietary and optimized anti-CD3 masking technology to reduce systemic toxicity and off-tumor effects
- Novel Pan-cancer Linker acts as tumor-specific switch, enabling precise unmasking and conditional activation and off-tumor effects
- Novel anti-CD3 Ab optimized for developability
- Tumor-associated antigen binding domain selected for optimal immune cell engagement
- Tumor targeting mask when target has more extensive expression in normal tissues
- Proprietary anti-HSA VHH for half-life extension & increased tumor exposure
INNOVATIVE OPPORTUNITIES FOR PREDATOR® PLATFORM
Our PREDATOR® protein-engineering technology allows us to create INDUKINE™ molecules for tissue-specific inflammatory diseases where modulating the immune system can offer therapeutic benefits while minimizing unwanted off-target effects in healthy tissues.
Non-Oncology INDUKINE™ Therapeutics
- Inflammation
- Other diseases
Expanding Conditional-Activation Technology to New Modalities
- Targeted antibodies and ADCs
- Cell-based therapies
- Disease-specific linkers